Celebrating Her Power, Gentle Shoulders Bearing Mountains and Rivers | Happy International Women's Day to the Goddesses of Entrepreneurship!
Her power knows no bounds.
道彤投资
@daltonventure
以生命科学为根，向硬科技生长
88 articles
Articles
Into the Dalton Family | Biolid: Where Seeds Can Be "Tailor-Made"
A pile of seeds sits before you — which ones will sprout fastest? Which will yield the most? Which will have the best quality? Traditional breeding requires months of careful observation in the field, taking at least three months of "looking, smelling, asking, and examining" to find answers. But at Shijiazhuang Biolid Biotechnology, it takes just 7 to 14 days. How is this possible? Welcome to **Dalton Venture Family company Biolid**, as we explore how Biolid spent eight years breaking foreign technology monopolies to successfully develop liquid-phase chip detection technology, dramatically shortening seed [text cuts off]
Inside Dalton Venture's Portfolio | As Medical AI Surges, Deepwise Health Moves First on a Trillion-Yuan Emerging Market
Deepwise's development has witnessed every major milestone in China's medical AI industry.
Rayton Bio Secures Dalton Venture Angel Round, Continues Leading Innovation in Long-Acting Sustained-Release Ocular Drug Delivery | Dalton News
Recently, **Shenzhen Ruitong Biomedical Co., Ltd.** (hereinafter referred to as "Ruitong Biomedical") **announced the completion of a tens-of-millions-of-yuan angel funding round**. This round was jointly invested by Dalton Venture, Qinzhi Capital, the National High-Performance Medical Device Innovation Center, and JenKem Technology (688356.SH). **The proceeds will be used to advance the company's core pipeline clinical trials and accelerate the technical development and pipeline expansion of its iSus® sustained-release platform**.
Steadfast Progress, Grounded in Action | Dalton Venture's 2024 Year in Review
Looking back at 2024, "adjustment" and "patience" became the defining keywords for venture capital. Yet on the long-distance track of life sciences and medtech, Dalton Venture kept moving forward with steady, deliberate strides. We navigated market fluctuations, caught glimpses of innovation, and helped companies take root and grow through the cycles — writing a new chapter of innovation-driven development with the power of capital.
Xiwi Microorganism Completes Nearly 100 Million Yuan Series A Funding Round Led by Dalton Venture, Building an Innovative Ophthalmic Biology and Polymer Materials Platform | Dalton Venture News
Recently, **Xiwei (Suzhou) Biomedical Technology Co., Ltd.** (hereinafter referred to as "Xiwei Biotech") **announced the completion of a nearly RMB 100 million Series A funding round, led by Dalton Venture**. The proceeds will be used to accelerate the development of its pipeline of ophthalmic and regenerative medicine innovations — including artificial biomimetic corneas, implantable contact lenses, artificial corneal endothelium sheets, and artificial dermis — as well as clinical trials, international regulatory registration, and marketing expansion.
Dalton Venture's Sun Qi: Mid-Game Mastery Goes to Those Who Adapt
Tune out the market noise and trust your own judgment.
Rooted in Reality, Driven by Innovation, Moving Forward Without Pause | Dalton Venture's 2024 Annual Partners Meeting Successfully Concludes
Pressing forward into the real, advancing toward the new — the resolve to push ahead undimmed.
21st Century Business Herald Interview | Dalton Venture's Sun Qi: Healthcare Is a Long, Snowy Slope — Time for Systematic Bets Is Here
In recent years, as the healthcare industry has yet to emerge from the capital winter, most investment firms have grown more cautious. Dalton Venture, however, has remained active on the investment front thanks to its distinctive strategy and deep understanding of the sector. Recently, **Sun Qi, founding and managing partner of Dalton Venture, sat down with 21st Century Business Herald for an exclusive interview, sharing his unique insights into healthcare industry trends and his confidence and determination to navigate through cycles.**
What Are the New Opportunities in Singapore's Capital Markets? | A Recap of the Dalton Venture x CICC Qimenghui Event
Building a company from founding to IPO is a long and arduous journey. For healthcare startups, the pursuit of technological breakthroughs runs parallel to challenges spanning corporate strategy, business models, capital operations, and day-to-day management.